Search
Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Ferric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency. … [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults.
Choline salicylate
go.drugbank.com/drugs/DB14006ApprovedNutraceuticalThis drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134]. … It is used to treat arthritis in both children and adults. This medicine can also be used for fever [L2129].
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Synonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexOteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalThe main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".
Escitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalEscitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. … [A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.
Categories: Monoamine Oxidase A SubstratesProducts: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg FilmtablettenHuman papillomavirus type 16 L1 capsid protein antigen
go.drugbank.com/drugs/DB10301ApprovedInvestigationalHuman papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Synonyms: L1 protein, Human papillomavirus type 16 Vaccine, Human papillomavirus type 16 L1 capsid protein antigenMixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETHuman papillomavirus type 18 L1 capsid protein antigen
go.drugbank.com/drugs/DB10302ApprovedInvestigationalHuman papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces
Synonyms: L1 protein, Human papillomavirus type 18 Vaccine, Human papillomavirus type 18 L1 capsid protein antigenMixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADETPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index